Accel-KKR-backed IntegriChain to merge with daVIZta

IntegriChain, which is backed by Accel-KKR, will merge with daVIZta, a provider of revenue analytics software for life sciences companies. No financial terms were disclosed.

PRESS RELEASE

Philadelphia, PA, March 6, 2019 – IntegriChain, a leading life sciences commercial data and analytics company that helps patients start therapy faster and stay on therapy longer, today announced that it will merge with daVIZta Inc. daVIZta is a leading provider of revenue analytics software, including gross-to-net (G2N) automation and government pricing solutions — key challenges for commercial-stage life sciences companies to ensure access to new and existing therapies — and serves as a trusted partner to large, mid-tier, and emerging life sciences manufacturers.

IntegriChain will integrate daVIZta’s G2N and government pricing offerings into its ICyte Platform, strengthening its best-in-class Payer solutions.

“This strategic merger solidifies our position as an access data and analytics leader through the expansion of our solutions platform and our team of data scientists and industry experts,” said IntegriChain Co-Founder and CEO Kevin Leininger. “Gross-to-net is a key industry obstacle for life sciences, with continuous headlines and regulatory uncertainty placing immense pressure on financial modeling and forecasting. We consider G2N a challenge on par with pharma’s patient initiation and adherence challenges, and we are serious about investing in and solving all three. The addition of daVIZta’s payer technology and expertise uniquely positions us to partner with industry to solve the G2N and pricing challenges of today and tomorrow.”

“We are excited to join forces with IntegriChain to overcome the access barriers that manufacturers face in today’s increasingly complex and evolving regulatory environment,” said Shekhar Yerramilli, Chairman and CEO of daVIZta. “IntegriChain offers our customers an extensive access solution platform, delivering unrivaled reporting, analytics, and on-demand data accessibility for all of the data inputs that are central to the G2N challenges we are passionate about solving. On behalf of my Co-Founder Krishnan Padmanabhan and myself, we look forward to working with IntegriChain’s customers on their G2N accrual management, forecasting, and government pricing requirements.”

This transaction is IntegriChain’s third expansion since entering its strategic partnership with Accel-KKR, a leading technology-focused private equity firm, in 2016. This merger creates a team of more than 220 data scientists and life sciences experts, including more than 20 government pricing, commercial contracting, and G2N domain experts focused on the critical dimensions of market access launch readiness, as well as government pricing compliance and G2N execution post-launch.

About IntegriChain
IntegriChain is a life sciences commercial data and analytics company that helps innovative bio/pharma manufacturers identify and remove barriers to patient therapy initiation and adherence. Our mission is to help all stakeholders in pharmaceutical access save as many patient days of therapy as possible. Our ICyte Platform and solutions uniquely focus on access challenges after the patient and provider commit to therapy. More than 160 life science manufacturers rely on insights delivered from IntegriChain’s data, analytics, and managed services to drive strategic decision-making and on-going business management across their payers, specialty pharmacies, patient services, and distribution channel partners.

IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA, and the company’s Access Management Operations center is in Ambler, PA. For more information, visit www.integrichain.com and our blog, or follow us on Twitter @IntegriChain and LinkedIn.

About daVIZta
daVIZta is a provider of Enterprise Revenue Analytics solutions and services to the life sciences industry. Our d-Rive suite of software applications caters to all aspects of the commercial continuum from Deal Modeling and Claims Processing to Government Pricing and G2N automation. Our subject matter experts in these areas provide managed services and advisory services to help our life sciences customers address their critical needs by relying on our deep domain knowledge. daVIZta sponsors the Revenue Analytics Collaborative, a unique and powerful community of industry insiders who share best practices and address each other’s concerns and day-to-day challenges. More information on daVIZta is available on www.davizta.com.

About Accel-KKR
Accel-KKR is a technology-focused investment firm with over $5 billion in capital commitments. The firm focuses on software and IT-enabled businesses well-positioned for top line and bottom-line growth. At the core of Accel-KKR’s investment strategy is a commitment to developing strong partnerships with the management teams of its portfolio companies and a focus on building value through significant resources available through the Accel-KKR network. Accel-KKR focuses on middle-market companies and provides a broad range of capital solutions including buyout capital, minority-growth investments, and credit alternatives. Accel-KKR also invests across a wide range of transaction types including private company recapitalizations, divisional carve-outs and going-private transactions. Accel-KKR is headquartered in Menlo Park with additional offices in Atlanta and London.